Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05578859 · ClinicalTrials.gov registry record · Phase 1
A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05578859 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 8 participants.
The verdict
NCT05578859, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objectives of the study are: to characterize the primary route(s) of elimination of \[14C\]-AMG 510 and drug-related material, and estimate the overall recovery of radiolabeled material in healthy male participants after oral administration of \[14C\]-AMG 510, and to characterize the pharmacokinetic (PK) of total radioactivity and AMG 510 following a single oral dose of \[14C\]-AMG 510 in healthy male participants.
Interventions
- DRUG AMG 510
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-03-11 |
| Est. Completion | 2020-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05578859
The ClinicalTrials.gov registry entry for NCT05578859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 510 is the first listed.
NCT05578859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05578859 about?
NCT05578859 is a clinical study titled "A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects". The primary objectives of the study are: to characterize the primary route(s) of elimination of \[14C\]-AMG 510 and drug-related material, and estimate the overall recovery of radiolabeled material in healthy male participants after oral administration of \[14C\]-AMG 510, and to characterize the pha...
What is the current status of trial NCT05578859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-03-11. Estimated completion is 2020-03-24.
What interventions are being tested in trial NCT05578859?
The interventions under investigation include: AMG 510 (DRUG).
Who is sponsoring clinical trial NCT05578859?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.